Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib

OBJECTIVE: Progression-free survival (PFS) is frequently used as an efficacy end point in oncology clinical trials. However, there is limited evidence to support a positive association between improvement in PFS and improvement in health-related quality of life (HRQoL). The association between PFS a...

Descripción completa

Detalles Bibliográficos
Autores principales: Griebsch, Ingolf, Palmer, Michael, Fayers, Peter M, Ellis, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216861/
https://www.ncbi.nlm.nih.gov/pubmed/25361836
http://dx.doi.org/10.1136/bmjopen-2014-005762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4216861/
https://www.ncbi.nlm.nih.gov/pubmed/25361836
http://dx.doi.org/10.1136/bmjopen-2014-005762

Ejemplares similares